Grassley: Deal to lower drug prices moving forward 'very soon'

Grassley: Deal to lower drug prices moving forward 'very soon'

Senate Finance Committee Chairman Chuck GrassleyCharles (Chuck) Ernest GrassleyMcSally unveils bill to lower drug prices amid tough campaign Ernst endorses bipartisan Grassley-Wyden bill to lower drug prices Overnight Health Care: Nevada union won't endorse before caucuses after 'Medicare for All' scrap | McConnell tees up votes on two abortion bills | CDC confirms 15th US coronavirus case MORE (R-Iowa) said Thursday that he plans to advance a bipartisan deal to lower drug prices “very soon.”

“While the final details are still being negotiated, we’re on track to report a bill out of committee very soon,” Grassley said in a statement. 

ADVERTISEMENT
Grassley has been in negotiations for months with Sen. Ron WydenRonald (Ron) Lee WydenHillicon Valley: Dems cancel surveillance vote after pushback to amendments | Facebook to ban certain coronavirus ads | Lawmakers grill online ticketing execs | Hacker accessed facial recognition company's database On The Money: Coronavirus complicates Fed decision on rates | Schumer wants .5B in emergency virus funding | Dems offer bill to reverse Trump on military money for wall Hillicon Valley: Democrats cancel surveillance vote over pushback to amendments | Lawmakers grill Ticketmaster, StubHub execs over online ticketing | MORE (Ore.), the panel’s top Democrat, and the pair are close to a deal, though there are still questions as to whether objections from other Republican senators on the committee could derail it. 

Several GOP senators are concerned that the agreement is coming too close to price controls on drugs, which Republicans traditionally oppose. 

There is still a question of how many GOP senators Grassley is willing to lose. But the statement Thursday indicates he is eager to push forward. 

A markup in committee could come as soon as next week or the week after, although lawmakers are still waiting for analysis from the Congressional Budget Office (CBO), which could prove pivotal in whether some lawmakers sign off on the agreement. 

The major point of GOP concern is a provision pushed by Wyden that would require drug companies to pay money back to Medicare’s prescription drug program, called Part D, if their prices rise faster than inflation, effectively putting a restraint on price increases in Medicare. 

Grassley on Wednesday defended the idea, saying it is similar to how Medicaid already works, and downplayed the concerns from other GOP senators. 

“If we do anything, there's plenty of precedent for it in Medicaid as an example, so we aren't doing anything new,” Grassley told reporters when asked about departing from GOP orthodoxy. 

Asked about GOP objections, Grassley responded: “I've heard some questions raised, but I haven't heard objection.”

“Because quite frankly you can't object to something that we don't have spelled out in statutory language, and if we had it in statutory language you couldn't react to it much until you get a CBO score,” he added. 

Sen. Lamar AlexanderAndrew (Lamar) Lamar AlexanderLawmakers raise alarms over Trump coronavirus response Bill Barr is trying his best to be Trump's Roy Cohn The Trump administration's harmful and immoral attack on children MORE (R-Tenn.) is pushing to vote on his own health care package, which could be combined with the drug pricing package if it is ready, before the end of July.  

But the clock is ticking on getting something done before lawmakers leave Washington for the August recess, a tough timeline to meet, especially with disagreements among GOP senators.